IAMOG
MDGL icon

Investors Asset Management of Georgia’s Madrigal Pharmaceuticals MDGL Stock Holding History

Investors Asset Management of Georgia’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-725
Closed -$203K – 169
2024
Q2 		$203K Sell
725
-150
-17% -$35.7K 0.1% 149
2024
Q1 		$234K Buy
+875
New +$206K 0.11% 138

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Investors Asset Management of Georgia's MDGL Position: Q3 2024 in Review

Investors Asset Management of Georgia sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2024, closing a stake of 725 shares — an estimated $203K sold.

Investors Asset Management of Georgia first reported a position in MDGL in Q1 2024 and held it in 2 quarters. The position peaked at $234K in Q1 2024. 257 funds tracked by Wall St. Rank hold MDGL as of Q3 2024.

  • Investors Asset Management of Georgia reported no remaining Madrigal Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Investors Asset Management of Georgia sold 725 Madrigal Pharmaceuticals shares in Q3 2024, an estimated $203K.
  • Investors Asset Management of Georgia first reported a position in Madrigal Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Investors Asset Management of Georgia's Madrigal Pharmaceuticals position peaked at $234K in Q1 2024.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2024.

Based on Investors Asset Management of Georgia's 13F filing for Q3 2024, filed 29 Oct 2024.